Den europeiske union - norsk - EMA (European Medicines Agency)

janssen-cilag international n.v. - teclistamab - multippelt myelom - antineoplastiske midler - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Den europeiske union - norsk - EMA (European Medicines Agency)

aop orphan pharmaceuticals gmbh - sugammadex sodium - neuromuskulær blokkade - alle andre terapeutiske produkter - reversering av nevromuskulær blokade indusert av rocuronium eller vecuronium. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Den europeiske union - norsk - EMA (European Medicines Agency)

fennec pharmaceuticals (eu) limited - sodium thiosulfate - ear diseases; ototoxicity - alle andre terapeutiske produkter - pedmarqsi is indicated for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to < 18 years of age with localised, non-metastatic, solid tumours.

Den europeiske union - norsk - EMA (European Medicines Agency)

extrovis eu ltd. - sugammadex sodium - neuromuskulær blokkade - alle andre terapeutiske produkter - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Norge - norsk - Statens legemiddelverk

baxter holding b.v. - sugammadeksnatrium - injeksjonsvæske, oppløsning - 100 mg/ ml

Norge - norsk - Statens legemiddelverk

bioglan ab - sugammadeksnatrium - injeksjonsvæske, oppløsning - 100 mg/ ml

Norge - norsk - Statens legemiddelverk

teva b.v. - sugammadeksnatrium - injeksjonsvæske, oppløsning - 100 mg/ ml